Jonathan E. Freeman - 17 Feb 2023 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)

Reporting relationship: Director
Issuer ticker: PHIO
Reported as of: 17 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Feb 2023, 18:25:15 UTC
Prior SEC filing: 16 Feb 2022
Next SEC filing: 13 Sep 2024
Source filing: View source filing
Reporting owner signature: Caitlin Kontulis, attorney-in-fact

Key filing fact

Jonathan E. Freeman filed Form 4 for Phio Pharmaceuticals Corp. (PHIO) on 22 Feb 2023.

Key facts

This page summarizes Jonathan E. Freeman's Form 4 filing for Phio Pharmaceuticals Corp. (PHIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Feb 2023, 18:25.

Change

Previous filing in this sequence was filed on 16 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHIO transaction

Common stock, $0.0001 par value

Award

Transaction value: $0
Shares: +1,500
Change %: +88%
Price: $0.000000
Shares after: 3,197
Date: 17 Feb 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

Footnote F2

Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 26, 2023, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-12.